MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$1,401,573
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from 2026 april registe...
Proceeds from issuance of common...
Accounts payable and accrued exp...
Others
Negative Cash Flow Breakdown
Net loss
Other receivable
Prepaid expenses
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-2,254,173
-1,680,982
-1,578,276
-1,992,790
Share-based compensation
200,537
258,287
294,794
294,793
Share-based payments to vendors
80,999
61,000
81,000
45,059
Other receivable
38,994
7,896
8,209
0
Prepaid expenses
4,258
143,808
-73,183
104,679
Accounts payable and accrued expenses
305,937
105,866
-47,232
-123,352
Net cash used in operating activities
-1,709,952
-1,407,533
-1,184,740
-1,880,969
Reverse stock split fractional share adjustment
-
-
0
1,040
Proceeds from warrant inducement, net of issuance costs
-
-
0
0
Proceeds from warrant exercise
-
-
1,360,544
-
Proceeds from issuance of common stock in connection with equity line of credit purchase agreement, net of issuance costs
839,667
3,106,246
1,473,494
1,724,683
Proceeds from 2025 march registered direct offering, net of issuance costs
-
-
0
0
Proceeds from 2025 january registered direct offering, net of issuance costs
-
-
0
0
Proceeds from 2026 april registered direct offering, net of issuance costs
2,271,858
-
-
-
Net cash provided by financing activities
3,111,525
3,106,246
2,834,038
1,723,643
Net increase in cash
1,401,573
1,698,713
1,649,298
-157,326
Cash at beginning of period
9,254,813
7,556,100
5,906,802
3,706,713
Cash at end of period
10,656,386
9,254,813
7,556,100
5,906,802
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from 2026 april
registered direct...
$2,271,858
Proceeds from issuance of
common stock in...
$839,667
(37.59%↑ Y/Y)
Net cash provided by
financing activities
$3,111,525
(-48.82%↓ Y/Y)
Net increase in cash
$1,401,573
(-40.55%↓ Y/Y)
Canceled cashflow
$1,709,952
Accounts payable and
accrued expenses
$305,937
(228.44%↑ Y/Y)
Share-based compensation
$200,537
(-69.51%↓ Y/Y)
Share-based payments to
vendors
$80,999
(-58.73%↓ Y/Y)
Net cash used in
operating activities
-$1,709,952
(54.06%↑ Y/Y)
Canceled cashflow
$587,473
Net loss
-$2,254,173
(48.72%↑ Y/Y)
Other receivable
$38,994
(457.12%↑ Y/Y)
Prepaid expenses
$4,258
(109.14%↑ Y/Y)
Buy us a coffee
Acurx Pharmaceuticals, Inc. (ACXP)
Acurx Pharmaceuticals, Inc. (ACXP)